Robinson Smith Wealth Advisors LLC Has $205,000 Stake in Regeneron Pharmaceuticals, Inc. $REGN

Robinson Smith Wealth Advisors LLC lessened its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 47.9% during the second quarter, HoldingsChannel reports. The institutional investor owned 390 shares of the biopharmaceutical company’s stock after selling 358 shares during the period. Robinson Smith Wealth Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $205,000 at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in REGN. Activest Wealth Management grew its position in shares of Regeneron Pharmaceuticals by 110.5% in the 1st quarter. Activest Wealth Management now owns 40 shares of the biopharmaceutical company’s stock valued at $25,000 after buying an additional 21 shares during the last quarter. Costello Asset Management INC acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Saudi Central Bank acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $27,000. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth about $31,000. Finally, Colonial Trust Advisors acquired a new stake in Regeneron Pharmaceuticals during the 1st quarter worth about $32,000. Institutional investors own 83.31% of the company’s stock.

Analysts Set New Price Targets

REGN has been the subject of a number of recent analyst reports. Jefferies Financial Group increased their price target on Regeneron Pharmaceuticals from $813.00 to $831.00 and gave the stock a “buy” rating in a report on Wednesday, August 27th. Canaccord Genuity Group restated a “buy” rating and issued a $850.00 target price on shares of Regeneron Pharmaceuticals in a research note on Thursday, October 23rd. Citigroup raised their target price on Regeneron Pharmaceuticals from $660.00 to $700.00 and gave the company a “buy” rating in a research note on Wednesday, October 29th. UBS Group restated a “neutral” rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Finally, Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the company an “overweight” rating in a research note on Wednesday, October 29th. Three equities research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $802.36.

Insider Buying and Selling

In related news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the transaction, the director owned 2,352 shares in the company, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $628.00 on Wednesday. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $844.51. The company’s 50 day moving average price is $584.01 and its two-hundred day moving average price is $566.40. The company has a quick ratio of 3.72, a current ratio of 4.06 and a debt-to-equity ratio of 0.09. The stock has a market cap of $66.56 billion, a P/E ratio of 15.04, a P/E/G ratio of 2.03 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 EPS for the quarter, topping the consensus estimate of $9.73 by $2.10. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The firm had revenue of $3.75 billion for the quarter, compared to analysts’ expectations of $3.57 billion. During the same quarter last year, the firm earned $12.46 EPS. The company’s quarterly revenue was up .9% compared to the same quarter last year. On average, equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Investors of record on Thursday, November 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 8.43%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.